275 related articles for article (PubMed ID: 34224739)
1. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
[TBL] [Abstract][Full Text] [Related]
2. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
[TBL] [Abstract][Full Text] [Related]
3. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.
Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M
Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851
[TBL] [Abstract][Full Text] [Related]
4. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
[TBL] [Abstract][Full Text] [Related]
5. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
Kucherlapati MH; Lee K; Nguyen AA; Clark AB; Hou H; Rosulek A; Li H; Yang K; Fan K; Lipkin M; Bronson RT; Jelicks L; Kunkel TA; Kucherlapati R; Edelmann W
Gastroenterology; 2010 Mar; 138(3):993-1002.e1. PubMed ID: 19931261
[TBL] [Abstract][Full Text] [Related]
6. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
[TBL] [Abstract][Full Text] [Related]
7. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M
Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080
[TBL] [Abstract][Full Text] [Related]
8. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention.
Bolivar AM; Duzagac F; Deng N; Reyes-Uribe L; Chang K; Wu W; Bowen CM; Taggart MW; Thirumurthi S; Lynch PM; You YN; Rodriguez-Pascual J; Lipkin SM; Kopetz S; Scheet P; Lizee GA; Reuben A; Sinha KM; Vilar E
Gastroenterology; 2024 May; 166(5):787-801.e11. PubMed ID: 38244726
[TBL] [Abstract][Full Text] [Related]
9. Towards a vaccine to prevent cancer in Lynch syndrome patients.
von Knebel Doeberitz M; Kloor M
Fam Cancer; 2013 Jun; 12(2):307-12. PubMed ID: 23760517
[TBL] [Abstract][Full Text] [Related]
10. Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies.
Sei S; Ahadova A; Keskin DB; Bohaumilitzky L; Gebert J; von Knebel Doeberitz M; Lipkin SM; Kloor M
Front Oncol; 2023; 13():1147590. PubMed ID: 37035178
[TBL] [Abstract][Full Text] [Related]
11. Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.
Kortüm B; Campregher C; Lang M; Khare V; Pinter M; Evstatiev R; Schmid G; Mittlböck M; Scharl T; Kucherlapati MH; Edelmann W; Gasche C
Gut; 2015 Dec; 64(12):1905-12. PubMed ID: 25429050
[TBL] [Abstract][Full Text] [Related]
12. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors.
Woerner SM; Tosti E; Yuan YP; Kloor M; Bork P; Edelmann W; Gebert J
Mol Carcinog; 2015 Nov; 54(11):1376-86. PubMed ID: 25213383
[TBL] [Abstract][Full Text] [Related]
13. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines.
Roudko V; Cimen Bozkus C; Greenbaum B; Lucas A; Samstein R; Bhardwaj N
Front Immunol; 2021; 12():757804. PubMed ID: 34630437
[TBL] [Abstract][Full Text] [Related]
14. A cancer vaccine approach for personalized treatment of Lynch Syndrome.
Majumder S; Shah R; Elias J; Manoharan M; Shah P; Kumari A; Chakraborty P; Kode V; Mistry Y; Coral K; Mittal B; Sm SM; Mahadevan L; Gupta R; Chaudhuri A; Khanna-Gupta A
Sci Rep; 2018 Aug; 8(1):12122. PubMed ID: 30108227
[TBL] [Abstract][Full Text] [Related]
15. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
Maletzki C; Schmidt F; Dirks WG; Schmitt M; Linnebacher M
Eur J Cancer; 2013 Jul; 49(11):2587-95. PubMed ID: 23561850
[TBL] [Abstract][Full Text] [Related]
16. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
[TBL] [Abstract][Full Text] [Related]
17. Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
Hernandez-Sanchez A; Grossman M; Yeung K; Sei SS; Lipkin S; Kloor M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732349
[TBL] [Abstract][Full Text] [Related]
18. The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients.
Bohaumilitzky L; Kluck K; Hüneburg R; Gallon R; Nattermann J; Kirchner M; Kristiansen G; Hommerding O; Pfuderer PL; Wagner L; Echterdiek F; Kösegi S; Müller N; Fischer K; Nelius N; Hartog B; Borthwick G; Busch E; Haag GM; Bläker H; Möslein G; von Knebel Doeberitz M; Seppälä TT; Ahtiainen M; Mecklin JP; Bishop DT; Burn J; Stenzinger A; Budczies J; Kloor M; Ahadova A
Gastroenterology; 2022 Mar; 162(3):907-919.e10. PubMed ID: 34863788
[TBL] [Abstract][Full Text] [Related]
19. A Thermosensitive Bi-Adjuvant Hydrogel Triggers Epitope Spreading to Promote the Anti-Tumor Efficacy of Frameshift Neoantigens.
Ke Y; Xin K; Tao Y; Li L; Chen A; Shao J; Zhu J; Zhang D; Cen L; Chu Y; Yu L; Liu B; Liu Q
Adv Sci (Weinh); 2024 Apr; 11(14):e2306889. PubMed ID: 38308098
[TBL] [Abstract][Full Text] [Related]
20. On the development of a neoantigen vaccine for the prevention of Lynch Syndrome.
Solomon A; Alteber Z; Bassan D; Sharbi-Yunger A; Esbit S; Tzehoval E; Eisenbach L
Int J Cancer; 2022 Jul; 151(1):107-119. PubMed ID: 35179790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
